These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32067336)

  • 41. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study.
    Zhao L; Tian L; Uno H; Solomon SD; Pfeffer MA; Schindler JS; Wei LJ
    Clin Trials; 2012 Oct; 9(5):570-7. PubMed ID: 22914867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.
    Stewart DJ; Bossé D; Goss G; Hilton JF; Jonker D; Fung-Kee-Fung M
    Crit Rev Oncol Hematol; 2020 Apr; 148():102896. PubMed ID: 32087510
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sample size calculation for the proportional hazards cure model.
    Wang S; Zhang J; Lu W
    Stat Med; 2012 Dec; 31(29):3959-71. PubMed ID: 22786805
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Joint modeling of progression-free survival and death in advanced cancer clinical trials.
    Dejardin D; Lesaffre E; Verbeke G
    Stat Med; 2010 Jul; 29(16):1724-34. PubMed ID: 20572123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Not too big, not too small: a goldilocks approach to sample size selection.
    Broglio KR; Connor JT; Berry SM
    J Biopharm Stat; 2014; 24(3):685-705. PubMed ID: 24697532
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biomarker threshold adaptive designs for survival endpoints.
    Diao G; Dong J; Zeng D; Ke C; Rong A; Ibrahim JG
    J Biopharm Stat; 2018; 28(6):1038-1054. PubMed ID: 29436940
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer.
    Foster NR; Renfro LA; Schild SE; Redman MW; Wang XF; Dahlberg SE; Ding K; Bradbury PA; Ramalingam SS; Gandara DR; Shibata T; Saijo N; Vokes EE; Adjei AA; Mandrekar SJ
    J Thorac Oncol; 2015 Jul; 10(7):1099-106. PubMed ID: 26134227
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts.
    Huet S; Tesson B; Jais JP; Feldman AL; Magnano L; Thomas E; Traverse-Glehen A; Albaud B; Carrère M; Xerri L; Ansell SM; Baseggio L; Reyes C; Tarte K; Boyault S; Haioun C; Link BK; Feugier P; Lopez-Guillermo A; Tilly H; Brice P; Hayette S; Jardin F; Offner F; Sujobert P; Gentien D; Viari A; Campo E; Cerhan JR; Salles G
    Lancet Oncol; 2018 Apr; 19(4):549-561. PubMed ID: 29475724
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.
    Sugimoto T; Sozu T; Hamasaki T; Evans SR
    Biostatistics; 2013 Jul; 14(3):409-21. PubMed ID: 23307913
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SOP 09: Statistical design and analysis.
    Onkologie; 2003 Oct; 26 Suppl 6():43-7. PubMed ID: 23570186
    [No Abstract]   [Full Text] [Related]  

  • 52. A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study.
    McClure LA; Szychowski JM; Benavente O; Hart RG; Coffey CS
    Clin Trials; 2016 Oct; 13(5):537-44. PubMed ID: 27094488
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of effect size and power for survival analysis through a binary surrogate endpoint in clinical trials.
    Abberbock J; Anderson S; Rastogi P; Tang G
    Stat Med; 2019 Feb; 38(3):301-314. PubMed ID: 30264471
    [TBL] [Abstract][Full Text] [Related]  

  • 55. When are "positive" clinical trials in oncology truly positive?
    Ocana A; Tannock IF
    J Natl Cancer Inst; 2011 Jan; 103(1):16-20. PubMed ID: 21131576
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Model free audit methodology for bias evaluation of tumour progression in oncology.
    Stone A; Macpherson E; Smith A; Jennison C
    Pharm Stat; 2015; 14(6):455-63. PubMed ID: 26435269
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A clinical trial design using the concept of proportional time using the generalized gamma ratio distribution.
    Phadnis MA; Wetmore JB; Mayo MS
    Stat Med; 2017 Nov; 36(26):4121-4140. PubMed ID: 28815655
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Testing of evaluation bias for progression free survival endpoint in oncology clinical trials.
    Sun Y; Wu W; Sargent D
    Stat Med; 2016 Sep; 35(22):3923-32. PubMed ID: 27089832
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Sample size calculation for the combination test under nonproportional hazards.
    Cheng H; He J
    Biom J; 2023 Apr; 65(4):e2100403. PubMed ID: 36789566
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Performance of randomization-based causal methods with and without integrating external data sources for adjusting overall survival in case of extensive treatment switches in placebo-controlled randomized oncology phase 3 trials.
    Nomura S; Shinozaki T; Hamada C
    J Biopharm Stat; 2020 Mar; 30(2):377-401. PubMed ID: 31820674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.